Jean Husten

发表

Comparison of LanthaScreen Eu kinase binding assay and surface plasmon resonance method in elucidating the binding kinetics of focal adhesion kinase inhibitors.

Jennifer L. Mason, C. Spais, T. Angeles, 2012, Assay and drug development technologies.

Serendipity in discovery of proteasome inhibitors.

M. Ator, Jean Husten, D. Dunn, 2012, Bioorganic & medicinal chemistry letters.

Proteasome inhibitors for cancer therapy.

M. Ator, Jean Husten, D. Dunn, 2012, Bioorganic & medicinal chemistry.

Serendipitous Discovery of a Prodrug of a PARP‐1 Inhibitor

M. Ator, Jean Husten, D. Dunn, 2013, Chemical biology & drug design.

Novel poly(ADP-ribose) polymerase-1 inhibitors.

M. Ator, Jean Husten, D. Dunn, 2007, Bioorganic & medicinal chemistry letters.

Higher Binding Affinity and In Vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab

L. Pukac, Jean Husten, D. Laine, 2018, Allergy, asthma & immunology research.

Synthesis and structure-activity relationships of novel pyrrolocarbazole lactam analogs as potent and cell-permeable inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).

G. Wells, M. Ator, Jean Husten, 2006, Bioorganic & medicinal chemistry letters.

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

Allison L. Zulli, R. Parchment, B. Ruggeri, 2007, Molecular Cancer Therapeutics.

Time-resolved fluorescence resonance energy transfer as a versatile tool in the development of homogeneous cellular kinase assays.

Jennifer L. Mason, C. Spais, T. Angeles, 2012, Assay and drug development technologies.

Novel poly(ADP-ribose) polymerase-1 inhibitors.

M. Ator, Jean Husten, D. Dunn, 2007, Bioorganic & medicinal chemistry letters.

Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models.

D. Bozyczko‐Coyne, A. Fedorov, E. Fedorov, 2008, Journal of Medicinal Chemistry.

Successful Identification of Glycine Transporter Inhibitors Using an Adaptation of a Functional Cell-Based Assay

Karla K Kopec, E. Duzic, C. Spais, 2009, Journal of biomolecular screening.

An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease

Jean Husten, A. Doyle, L. Poulton, 2018, mAbs.

Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases.

Jennifer L. Mason, P. Dobrzanski, K. L. Milkiewicz, 2012, Bioorganic & medicinal chemistry letters.

Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors.

K. L. Milkiewicz, T. Underiner, B. Dorsey, 2011, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors.

G. Wells, M. Ator, Jean Husten, 2006, Bioorganic & medicinal chemistry letters.

Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.

K. L. Milkiewicz, S. Miknyoczki, T. Underiner, 2011, Bioorganic & medicinal chemistry.